Angiolillo, Dominick J; Cao, Davide; Sartori, Samantha; Baber, Usman; Dangas, George; Zhang, Zhongjie; Vogel, Birgit; Kunadian, Vijay; Briguori, Carlo; Cohen, David J; +23 more... Collier, Timothy; Dudek, Dariusz; Gibson, Michael; Gil, Robert; Huber, Kurt; Kaul, Upendra; Kornowski, Ran; Krucoff, Mitchell W; Ielasi, Alfonso; Stefanini, Giulio G; Pivato, Carlo A; Mehta, Shamir; Moliterno, David J; Ohman, E Magnus; Escaned, Javier; Sardella, Gennaro; Sharma, Samin K; Shlofmitz, Richard; Weisz, Giora; Witzenbichler, Bernhard; Steg, P Gabriel; Pocock, Stuart; Mehran, Roxana; (2023) Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. JACC. Cardiovascular interventions, 16 (20). pp. 2514-2524. ISSN 1936-8798 DOI: https://doi.org/10.1016/j.jcin.2023.08.019
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases. OBJECTIVES: The authors sought to evaluate the incidence, predictors, and outcomes of dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention (PCI). METHODS: In the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. The occurrence of dyspnea associated with ticagrelor discontinuation was evaluated among all patients enrolled in the trial. A landmark analysis was performed at 3 months after PCI, that is, the time of randomization. Predictors of dyspnea-related ticagrelor discontinuation were obtained from multivariable Cox regression with stepwise selection of candidate variables. RESULTS: The incidence of dyspnea-related ticagrelor discontinuation was 6.4% and 9.1% at 3 and 15 months after PCI, respectively. Independent predictors included Asian race (lower risk), smoking, prior PCI, hypercholesterolemia, prior coronary artery bypass, peripheral artery disease, obesity, and older age. Among 179 patients who discontinued ticagrelor because of dyspnea after randomization, ticagrelor monotherapy was not associated with a higher risk of subsequent ischemic events (composite of all-cause death, myocardial infarction, or stroke) compared with ticagrelor plus aspirin (5.0% vs 7.1%; P = 0.566). CONCLUSIONS: In the TWILIGHT trial, dyspnea-related ticagrelor discontinuation occurred in almost 1 in 10 patients and tended to occur earlier rather than late after PCI. Several demographic and clinical conditions predicted its occurrence, and their assessment may help identify subjects at risk for therapy nonadherence.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Medical Statistics |
PubMed ID | 37879803 |
Elements ID | 210411 |
Official URL | http://dx.doi.org/10.1016/j.jcin.2023.08.019 |
Download
Embargo Date: 23 October 2024
Restricted to: Repository staff only
Filename: Dominick_etal_2023_Dyspnea-Related-Ticagrelor-Discontinuation-After.pdf
Description: This is an author accepted manuscript version of an article accepted for publication and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0